7th International Bone Marrow Failure Disease Scientific Symposium
Virtual Agenda - July 15, 16 & 17, 2020

Wednesday, July 15, 2020 - 9:30 am to 12:00 noon EDT

9:30 – 9:35 am  Welcome & Opening Remarks
Symposium Co-Chairs Richard Stone, MD, Dana-Farber Cancer Institute and Neal Young, MD, National Heart, Lung, and Blood Institute

Genetics and Genomics of Bone Marrow Failure
Co-Chairs: Jaroslaw Maciejewski, MD, PhD, Cleveland Clinic
Austin Kulasekararaj, MBBS MD MRCP FRCPath, Kings College Hospital

9:35 – 10:00 am  Acquired abnormalities in BMF – focus on HLA mutations
Daria Babushok, MD, PhD, University of Pennsylvania

10:00 – 10:30 am  Novel syndromes predisposing to BMF/MDS
Marcin Wlodarski, MD, PhD, St. Jude Children’s Research Hospital

10:30 – 11:00 am  Germline predisposition in late onset BMF/MDS
Jaroslaw Maciejewski, MD, PhD, Cleveland Clinic

11:00 – 11:30 am  Mechanisms of Somatic Transformation in SDS Patients
R. Coleman Lindsley, MD, PhD, Dana-Farber Cancer Institute

11:45 – 12:00 pm  Session Discussion
Thursday, July 16 – 9:30 am to 12:00 noon EDT

Transplantation for Bone Marrow Failure
Co-Chairs: H. Joachim Deeg, MD, Fred Hutchinson Cancer Center
Antonio Risitano, MD, PhD, University of Naples

9:30 – 10:00 am  Conventional and Haplo-identical transplants
Amy E. DeZern, MD, MHS, Johns Hopkins

10:00 – 10:30 am  Transplantation for Inherited Bone Marrow Failure Disorders and Fanconi Anemia
- Lauri Burroughs, MD, Seattle Cancer Care or Carmen Bonfim, MD, PhD, University of Parana

Non-transplant Therapies for Marrow Failure
Co-Chairs: Phillip Scheinberg, MD, University of Sao Paolo and Neal Young, MD, NHLBI

10:30 – 10:45 am  RACE Study Update
Antonio Risitano, MD, PhD, University of Naples

10:45 – 11:15 am  NIH Long Term Follow-up
Bhavisha Patel, MD, National Heart, Lung, and Blood Institute

11:15 – 11:45 am  Future Directions in Non-Transplant Therapies
Phillip Scheinberg, MD, University of Sao Paolo and Neal Young, MD, NHLBI

11:45 – 12:00 pm  Session Discussion
Friday, July 17 – 9:30 am to 12:00 noon EDT

Treatments for MDS and Secondary AML
Co-Chairs: Olatoyosi Odenike, MD, University of Chicago and David Sallman, MD, Moffitt Cancer Center

9:30 – 10:00 am Novel strategies for TP53 mutated AML/MDS
David Sallman, MD, Moffitt Cancer Center

10:00 – 10:30 am TGF beta inhibition in MDS
Amit Verma, MD, Albert Einstein College of Medicine

10:30 – 11:00 am Spliceosome modulation as a target in MDS
Timothy Graubert, MD, Massachusetts General Hospital

11:00 – 11:30 am Oral azanucleosides and novel combination strategies in higher risk MDS
Olatoyosi Odenike, MD, University of Chicago

11:30 – 12:00 noon Session Discussion